Etuvetidigene autotemcel

Brand names: Waskyra · Active ingredient: Etuvetidigene Autotemcel

In short: WASKYRA® is indicated for the treatment of pediatric patients aged 6 months and older and adults with Wiskott-Aldrich Syndrome (WAS) who have a mutation in the WAS gene and for whom hematopoietic stem cell transplantation (HSCT) is appropriate and no suitable human leukocyte antigen (HLA)-matched re

Forms & strengthsWASKYRA® is a single-dose cell suspension for intravenous infusion. WASKYRA® is provided in one to eight infusion bags which contain 2–11.4 x 106 cells/mL (1.9–11.4 x 106 CD34+ cells/mL) . Each infusion bag contains 10 to 20 mL of WASKYRA®. …
LabelOrphan Therapies LLC
Label updatedJul 24, 2026

What is Etuvetidigene autotemcel used for?

WASKYRA® is indicated for the treatment of pediatric patients aged 6 months and older and adults with Wiskott-Aldrich Syndrome (WAS) who have a mutation in the WAS gene and for whom hematopoietic stem cell transplantation (HSCT) is appropriate and no suitable human leukocyte antigen (HLA)-matched related stem cell donor is available.

Etuvetidigene autotemcel dosage

For autologous use only. For single-dose intravenous use only.

The minimum recommended dose of WASKYRA® is 7 × 106 CD34+ cells/kg based on patient’s body weight at the time of infusion.

The maximum volume of WASKYRA® to be administered should remain < 20% of the patient’s estimated plasma volume.

Mobilization and apheresis

Mobilize hematopoietic stem and progenitor cells (HSPC) using G-CSF with plerixafor according to established protocols.

Perform apheresis to collect CD34+ cells required for WASKYRA® manufacturing following the mobilization procedure.

Collect and cryopreserve a back-up supply of CD34+ stem cells containing at least 3 x 10⁶ CD34+ cells/kg from the patient. Complete this collection before initiating reduced intensity conditioning and WASKYRA® infusion.

Store the back-up collection for potential rescue treatment in the following scenarios: WASKYRA® compromise after reduced intensity conditioning initiation but before scheduled infusion, primary engraftment failure, or prolonged bone marrow aplasia following WASKYRA® treatment.

Pre-treatment and conditioning

Administer rituximab (anti-CD20 monoclonal antibody) approximately 22 days before WASKYRA® administration to deplete autoreactive B-cells and provide pre-emptive treatment for potential lymphoproliferative disorder due to Epstein Barr Virus infection which is a risk factor in WAS patients.

Administer busulfan and fludarabine for reduced intensity conditioning before infusion of WASKYRA® to promote engraftment of the genetically modified autologous CD34+ cells.

Do not begin conditioning until the complete set of infusion bag(s) constituting the dose of WASKYRA® has been received and stored at the administration site. Confirm availability of the back-up collection.

Premedication

Administer intravenous chlorpheniramine (0.2 mg/kg, max. dose 10 mg), or an equivalent 15-30 minutes before the infusion of WASKYRA® to reduce the possibility of an allergic reaction to the infusion.

Receipt

WASKYRA® is shipped in the vapor phase of liquid nitrogen (<-130°C; -202°F) from the manufacturing site to the qualified treatment center for the infusion. The Lot Information Sheet and the Chain of Custody documentation travels with the cryoshipper.

Upon arrival check the temperature on the display of the cryoshipper, open it using the proper DPI, and confirm the patient code, batch number and number of bags against product label(s).

Transfer WASKYRA® from the vapor phase of liquid nitrogen at less than -130°C (-202°F) to the treatment center vapor phase of liquid nitrogen storage (<-130°C; -202°F) until ready for thaw and administration.

In the event of issues, contact Fondazione Telethon ETS at: 1-888-212-6928. …

How to take Etuvetidigene autotemcel — instructions & advice from the label

Ensure that patients and/or caregivers understand the risk of manufacturing failure. A collection of unmanipulated back-up CD34+ cells is required in case of manufacturing failure. These cells must be collected from the patient and be cryopreserved prior to conditioning.

Prior to treatment, discuss following with the patients and/or caregivers:

Risk of hypersensitivity reactions - Although no cases have been reported to date, allergic reactions may occur with the infusion of WASKYRA®. The DMSO in WASKYRA® may cause hypersensitivity reactions, including anaphylaxis .

Failure of engraftment is a potentially important risk .

Risks of severe cytopenias. Patients should be monitored for signs and symptoms of cytopenia for at least 6 weeks after infusion .

Risk of serious infections have occurred with WASKYRA® administration . Increased susceptibility to infections may occur to concomitant administration of rituximab and conditioning regimen. Patients should be monitored for signs and symptoms of infection before and after WASKYRA® infusion and treat appropriately. Any blood product required after WASKYRA® infusion should be irradiated (5.4). …

Warnings & precautions

Do not take this medicine if: Hypersensitivity to the active substance or to any of the excipients .

Previous treatment with HSCT within 6 months prior to treatment or HSCT with evidence of residual donor cells.

Previous treatment with hematopoietic stem cell gene therapy.

Contraindications to the mobilization and the conditioning regimen.

Hypersensitivity and infusion related reactions, including anaphylaxis may occur with WASKYRA® infusion due to DMSO as an excipient in WASKYRA®. Monitor patients for signs and symptoms of hypersensitivity and infusion-related reactions during and after the WASKYRA® infusion.

When more than one bag of WASKYRA® is needed, prior to infusion it should be ensured that the volume of product to be infused is compatible with the recommended limit of DMSO, i.e., the total volume of DMSO administered should remain < 1% of the patient’s estimated plasma volume. The maximum volume of WASKYRA® to be administered should therefore remain < 20% of the patient’s estimated plasma volume. Also, when more than one bag of WASKYRA® is needed, only one bag of medicinal product should be infused at a time.

Engraftment failure defined as failure to reach an absolute neutrophil count (ANC) > 500 cells/μL associated with no evidence of bone marrow recovery (i.e., hypocellular marrow) by day 60 may potentially occur after WASKYRA® infusion. Monitor patients for signs and symptoms of engraftment failure. In case of engraftment failure, infuse the non-transduced back-up hematopoietic stem cells according to local standards.

Severe cytopenias, including anemia, neutropenia, and thrombocytopenia have occured for several weeks following reduced intensity conditioning and WASKYRA® infusion .

Monitor patients for signs and symptoms of cytopenia for at least 8 weeks after treatment with WASKYRA®. …

Etuvetidigene autotemcel side effects

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety data described in this section reflects exposure to WASKYRA® in two clinical studies, Study 1 (201228) and Study 2 (OTL-103-4) as well as patients in expanded access program (EAP). A total of 27 patients received a single infusion of WASKYRA® at a dose range of 7 to 31×106 CD34+ cells/kg (median dose: 16.90×106 CD34+ cells/kg). The median duration of the follow up was 5.67 years (range: 0.37-13.26 years) .

During the above-mentioned clinical trials no adverse reactions attributable to the gene therapy were reported. There were 45 serious adverse reactions reported in 21 patients including catheter-related infections (n=11), bacterial and viral infections (n=10), pyrexia (n=3), prolonged neutropenia (n=2), vomiting (n=2), veno-occlusive disease (n=1), aspergillus infection (n=1). One patient died approximately 4.5 months after WASKYRA® infusion due to neurological decompensation.

Adverse Reactions | Any Graden (%) | Grade 3 or higher

n (%)

Infections and Infestations | - | -

Catheter related infection | 16 (59) | 14 (52)

Respiratory tract infectionIs a composite that includes multiple related terms. …

Drug interactions

No formal drug interaction studies have been performed. WASKYRA® is not expected to interact with the hepatic cytochrome P-450 family of enzymes or drug transporters.

The safety and effectiveness of vaccination during or following WASKYRA® treatment have not been studied. Vaccination with live virus vaccines is not recommended until immune reconstitution is completed following treatment with WASKYRA®.

Anti-retroviral medications may interfere with the manufacturing of WASKYRA®. Patients should not take anti-retroviral medications for at least one month prior to mobilization until at least 7 days after WASKYRA® infusion. If a patient requires anti-retroviral treatment following exposure to HIV/HTLV, initiation of WASKYRA® treatment should be delayed until an HIV/HTLV western blot and viral load assay have been performed at 6 months post-exposure.

About this medicine

WASKYRA® (etuvetidigene autotemcel) is an autologous hematopoietic stem cell-based gene therapy for intravenous infusion.

WASKYRA® is prepared from the patient’s own hematopoietic stem cells (HSCs), which are collected using apheresis procedure(s). The autologous cells are enriched for CD34+ cell and then transduced ex vivo with a replication incompetent self-inactivating (SIN) human immunodeficiency virus-1 (HIV-1)-based lentiviral vector (LVV) that has been modified to carry the WAS gene sequence under the control of the human WAS promoter. The transduced CD34+ cells are washed, formulated into a suspension, and then cryopreserved.

WASKYRA® is manufactured for each individual patient into infusion bags, which are cryopreserved before being thawed prior to administration .

The formulation contains 7% (w/v) human serum albumin (HSA) and 5% (v/v) dimethyl sulfoxide (DMSO). Each 1mL of WASKYRA® suspension for IV infusion contains 3.5 mg of sodium. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 106880df-7a30-4a0f-9e16-9f20fcc7d138. Read the full official label on DailyMed.